GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 10.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 192,612 shares of the company’s stock after buying an additional 17,633 shares during the period. Bank of New York Mellon Corp owned 0.05% of GoodRx worth $896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in GDRX. Fortem Financial Group LLC purchased a new stake in GoodRx during the third quarter worth approximately $772,000. Barclays PLC raised its holdings in GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after purchasing an additional 130,219 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in GoodRx by 5.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 480,123 shares of the company’s stock worth $3,332,000 after purchasing an additional 26,262 shares in the last quarter. IMC Chicago LLC acquired a new position in shares of GoodRx in the 4th quarter valued at $304,000. Finally, Pier Capital LLC purchased a new position in shares of GoodRx in the 3rd quarter valued at $3,259,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Down 1.9 %

NASDAQ:GDRX opened at $4.55 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -151.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a one year low of $4.09 and a one year high of $9.26. The stock has a 50-day simple moving average of $4.76 and a 200 day simple moving average of $5.35.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GDRX shares. Wells Fargo & Company decreased their price objective on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Citigroup decreased their price target on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Morgan Stanley reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Mizuho started coverage on shares of GoodRx in a research note on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price for the company. Finally, KeyCorp dropped their price target on GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, GoodRx currently has a consensus rating of “Moderate Buy” and an average price target of $8.18.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.